Development asset linked to Pacalis Therapeutics Pty in public FDA and regional records.
pharma · Pompe Disease (Late-onset) · Fabry Disease
Pacalis Therapeutics Pty
AMICUS THERAPEUTICS PTY LTD
Pacalis Therapeutics Pty drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
melbourne, AU HQ
2023 Founded
1 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- melbourne, AU
- Founded
- 2023
- Employees
- 1
- Programs
- 5
- Drugs
- 6
- Patents
- 0
Pacalis Therapeutics Pty pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pacalis Therapeutics Pty drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
cipaglucosidase alfa
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Pacalis Therapeutics Pty's portfolio. Molecular target: Glycogen.
- Target
- Glycogen
- Mechanism
- Glycogen hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Glycogen.
- Target
- Glycogen
- Mechanism
- Glycogen hydrolytic enzyme
-
migalastat
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Pacalis Therapeutics Pty's portfolio. Molecular target: Alpha-galactosidase A.
- Target
- Alpha-galactosidase A
- Mechanism
- Alpha-galactosidase A stabiliser
-
US regulatory status: approved. Molecular target: Alpha-galactosidase A.
- Target
- Alpha-galactosidase A
- Mechanism
- Alpha-galactosidase A stabiliser
-
Development asset linked to Pacalis Therapeutics Pty in public FDA and regional records.